Sugi Predict

Sugi Predict / Compounds / SCHEMBL610098

SCHEMBL610098

SCHEMBL610098

COC(=O)c1c(C)cc(Br)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.55
▸ ACHE P22303 1/20 0.55
▸ HPGD P15428 2/20 0.52
▸ POLB P06746 1/20 0.46
▸ GLO1 Q04760 1/20 0.45
▸ NOTUM Q6P988 1/20 0.44
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA7 P43166 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ CA14 Q9ULX7 2/20 0.43
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ PRKCZ Q05513 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20561796 0.88 CYP3A4 (0.68) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL3839260 0.87 CYP3A4 (0.47) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL612875 0.87 CYP3A4 (0.47) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL2024646 0.87 CYP3A4 (0.49) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL17419113 0.87 CYP3A4 (0.47) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL29927434 0.87 CYP3A4 (0.49) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL20562234 0.85 CYP3A4 (0.46) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL29400731 0.84 CYP3A4 (0.45) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL27241564 0.84 ERN1 (0.46) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL1104456 0.84 CYP3A4 (0.45) CYP3A4ACHEHPGDPOLBGLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 — — US disclosed
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 — — EP disclosed
US-12410170-B2 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds ARCUS BIOSCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 — — EP disclosed
CN-115611883-B PI3K alpha inhibitor with double-ring structure, and preparation method and application thereof 生物岛实验室 2025-03-28 — — CN disclosed
CN-119638687-A Aromatic heterocyclic pyrrolidones and uses thereof 杭州百新生物医药科技有限公司 2025-03-18 — — CN disclosed
WO-2025026270-A1 BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2025-02-06 — — WO disclosed
WO-2025003769-A2 AROMATIC HETEROCYCLIC PYRROLIDONE DERIVATIVE AND USE THEREOF 杭州百新生物医药科技有限公司 2025-01-02 — — WO disclosed
WO-2024256988-A1 SMARCA2 DEGRADERS AND USES THEREOF ASTRAZENECA AB (SE) 2024-12-19 — — WO disclosed
EP-4426289-A1 AKT3 MODULATORS Georgiamune Inc. (US) 2024-09-11 — — EP disclosed
US-20090111830-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2009-04-30 — — US disclosed
WO-2008130853-A1 HYDRAZIDES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 681 ASTRAZENECA AB (SE) 2008-10-30 — — WO disclosed
US-20080227794-A1 Metabotropic Glutamate-Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2008-09-18 — — US disclosed
US-20080227794-A1 Metabotropic Glutamate-Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2008-09-18 — — US disclosed
US-7417169-B2 Amino alcohol derivatives, medicinal composition containing the same, and use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-08-26 — — US disclosed
EP-1778634-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2007-05-02 — — EP disclosed
US-20070078184-A1 Amino alcohol derivatives, medicinal composition containing the same, and use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-04-05 — — US disclosed
EP-1679304-A1 AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE Kissei Pharmaceutical Co., Ltd. (JP) 2006-07-12 — — EP disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410170-B2 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds PIK3CA, PIK3CG, PIK3CD CYP3A4 3613/4885ACHE 4832/4885HPGD 1825/4885
US-20090111830-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS GRM1, GRIN1, GRM2 CYP3A4 1112/4885ACHE 1071/4885HPGD 1135/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 CYP3A4 1190/4885ACHE 3231/4885HPGD 1044/4885
US-20070078184-A1 Amino alcohol derivatives, medicinal composition containing the same, and use of these ADRB2, ADRA2A, ADRA1A CYP3A4 101/4885ACHE 486/4885HPGD 1970/4885
US-20080227794-A1 Metabotropic Glutamate-Receptor-Potentiating Isoindolones GRM1, GRIN1, GRM2 CYP3A4 1532/4885ACHE 849/4885HPGD 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.